Teva Pharmaceutical details Copaxone CHMP opinion, shares tracked on NYSE

Teva Pharmaceutical outlines the impact of a recent CHMP opinion on a key multiple sclerosis drug while investors watch the NYSE-listed shares against peers like Pfizer and Novartis.

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-26, 17:19.

Teva Pharmaceutical Industries Ltd. (US88162G1031) has drawn attention after a recent Committee for Medicinal Products for Human Use (CHMP) opinion affecting its multiple sclerosis portfolio in Europe, as reported in regulatory updates. The generics and specialty drug maker is listed on the NYSE alongside peers such as Pfizer and Novartis.

CHMP opinion and MS franchise

The CHMP recently issued an opinion relating to a Teva product in the multiple sclerosis segment, according to European Medicines Agency documentation, with implications for certain marketed indications in the European Union. This comes as Teva continues to manage the lifecycle of Copaxone, its long-standing MS therapy, in a competitive landscape that includes Novartis and Biogen.

Regulatory assessments by bodies such as the CHMP typically focus on updated safety and efficacy data over a product’s lifecycle, and an opinion can lead to changes in labeling, indications, or risk management plans. For Teva, such outcomes are relevant because Copaxone and its follow-on formulations have historically contributed a material share of specialty revenue, even as US and EU sales have come under pressure from generic glatiramer acetate competitors.

Analyst focus on debt reduction and pipeline

Equity analysts covering Teva on Wall Street have in recent months emphasized the company’s strategy of using cash flow from both generics and branded drugs to reduce its sizeable debt pile and to fund a more focused pipeline. Broker commentary from houses such as JPMorgan and UBS in 2026 has frequently highlighted progress on leverage ratios and the potential contribution of newer specialty and biosimilar launches relative to legacy products like Copaxone.

Consensus data collected by market platforms in June 2026 point to a mixed but stabilizing view on Teva, with a spread of Buy, Hold, and Sell ratings reflecting differing assessments of litigation exposure, pricing dynamics in US generics, and the sustainability of cash generation. The CHMP opinion on an MS product fits into this broader narrative, as any change in European sales expectations can slightly shift models for 2026 and 2027, although the MS portfolio is now a smaller driver than in the peak Copaxone years.

The product behind the stock

Teva’s best-known branded neurology product remains Copaxone, a glatiramer acetate formulation used for the treatment of relapsing forms of multiple sclerosis. While generic competition has reduced sales from earlier peaks, the drug continues to contribute cash flow that supports pipeline investments and debt reduction efforts.

Where the stock trades today

Teva Pharmaceutical shares most recently changed hands on the NYSE at around 14.50 US dollars, based on intraday data on 2026-06-26, 15:00 UTC.

Teva Pharmaceutical at a glance

• Company: Teva Pharmaceutical Industries Ltd.
• ISIN: US88162G1031
• WKN: 883035
• Ticker: TEVA
• Trading venue: NYSE
• Price (as of 2026-06-26, 15:00): 14.50 USD
• Market cap: 16.0 billion USD (as of 2026-06-26)
• Sector / industry: Pharmaceuticals / Generics and Specialty
• Index membership: Not a member of the S&P 500
• Next earnings date: not officially scheduled

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.